Thromboxane generation and platelet aggregation in survivals of myocardial infarction.
Arachidonic acid (AA)-induced platelet aggregation was studied in platelet-rich plasma of 30 male patients who survived myocardial infarction and in 30 healthy men of similar age. Mean platelet aggregation thresholds to AA were 746 +/- 62 micrometer, and 869 +/- 57 micrometer, respectively. Only in 2 healthy subjects, but in 12 patients, irreversible platelet aggregation was induced consistently with low concentrations of AA, under 500 micrometer. The rate of conversion of AA to thromboxane A2 (TXA2) by platelets of these patients was augmented. Furthermore, less endogenous TXA2 was required to trigger aggregation of their platelets as compared to the controls. We have also shown that in platelet-poor plasma of these patients with "hyperreactive" platelets there exists a transferable factor which makes platelets of healthy subjects more prone to aggregatory action of AA. It is proposed that the assessment of platelet aggregability with AA provides a tool for identifying a subgroup of patients with coronary heart disease who might substantially benefit from the secondary preventive treatment with aspirin and with other antiplatelet drugs which inhibit the generation of TXA2 in platelets.
D000328:Adult; D000368:Aged; D001095:Arachidonic Acids / Q000494:pharmacology; D001772:Blood Cell Count; D001792:Blood Platelets; D002784:Cholesterol / Q000097:blood; D006801:Humans; D007213:Indomethacin / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood*; D010974:Platelet Aggregation; D013928:Thromboxane A2 / Q000096:biosynthesis; D013931:Thromboxanes / Q000096:biosynthesis*; D014280:Triglycerides / Q000097:blood
D001095:Arachidonic Acids; D013931:Thromboxanes; D014280:Triglycerides; D013928:Thromboxane A2; D002784:Cholesterol; D007213:Indomethacin